|Bid||3.6500 x 900|
|Ask||3.6900 x 1100|
|Day's range||3.6000 - 4.2499|
|52-week range||3.6000 - 13.6400|
|Beta (5Y monthly)||0.92|
|PE ratio (TTM)||N/A|
|Earnings date||09 Feb 2022 - 14 Feb 2022|
|Forward dividend & yield||N/A (N/A)|
|1y target est||16.67|
STONY BROOK, N.Y., January 21, 2022--Applied DNA submits a request for EUA to FDA for Linea 2.0 Assay and Linea Collection Kit; prepares for nationwide service rollout upon authorization.
STONY BROOK, N.Y., January 18, 2022--FQ1’22 COVID-19 Testing Levels Up Over 90% Compared to FQ4’21; Company Reports Further Strengthening in FQ2’22 to Date.
STONY BROOK, N.Y., January 04, 2022--Applied DNA's ADCL receives conditional approval from NYSDOH for Linea 2.0 COVID-19 Assay; Intends to file near-term EUA for assay and at-home kit.